Hepion Pharmaceuticals, INC 10-Q quarterly reports

Hepion Pharmaceuticals' Q2 2026 report highlights significant operating losses, a substantial accumulated deficit, and material weaknesses in internal controls, raising concerns about its ability to continue as a going concern despite recent financing.

Hepion Pharmaceuticals reports Q1 2026 results with reduced operating expenses but continues to face going concern uncertainties, while also announcing a new diagnostic asset license.

Hepion Pharmaceuticals shifts focus to medical diagnostics after winding down its liver disease drug program, reporting reduced net losses and improved cash position despite Nasdaq delisting.

Hepion Pharmaceuticals shifts from drug development to diagnostics after clinical trial wind-down and failed merger, securing new licenses while navigating Nasdaq delisting and persistent financial challenges.

Hepion Pharmaceuticals reports Q1 2025 results, including a net loss of $6.1 million, and enters into a license agreement with New Day Diagnostics for certain diagnostic tests.

Hepion Pharmaceuticals reported its Q3 2024 results, highlighting a significant decrease in operating expenses and ongoing strategic restructuring efforts, including a planned merger with Pharma Two B Ltd.

Hepion Pharmaceuticals reported its Q2 2024 financial results, highlighting ongoing strategic restructuring efforts and a planned merger with Pharma Two B Ltd.

Hepion Pharmaceuticals announced its first quarter 2024 financial results, alongside the wind-down of its ASCEND-NASH clinical trial and ongoing exploration of strategic alternatives.